Dr. Peter van Luijk is an Associate Professor at the Faculty of Medical Sciences of the University of Groningen. His research focuses on Radiobiology , Mathematical & Computational Biology , and Oncology , with a particular emphasis on radiation effects in tissues and improving treatment outcomes through advanced modeling and proton therapy optimization. Expertise includes: Radiation-induced tissue damage mechanisms, predictive modeling of normal tissue complications, and translational research bridging physics and clinical oncology. Collaborates in the ESTRO DREAM Team , a multidisciplinary initiative advancing radiotherapy response prediction. Received a €1.5M grant from KWF for research into mitigating radiation side effects. His work integrates experimental, computational, and clinical approaches to address challenges in thoracic and head/neck radiation therapies, emphasizing patient-specific risk assessment and novel therapeutic strategies.
Professor Myron Christodoulides is a leading academic in the field of Bacteriology at the University of Southampton . His research focuses on developing vaccines , novel antimicrobials , and rapid diagnostics for bacterial pathogens affecting humans and animals, with global collaborations. He is affiliated with the Institute for Life Sciences and holds the Academy of Medical Sciences Hamied Foundation UK-India AMR Visiting Professorship . Research Interests : Bacterial pathogenesis, Leishmania, Neisseria meningitidis, AI-driven diagnostics, nanotechnology applications in microbiology, and host-pathogen interactions. Supervision : Currently supervises Michael Mohsen Kamel Girgis in Infection, Inflammation & Immunity. Scientific Contributions : Recent publications highlight innovations in Metal-organic frameworks against Neisseria gonorrhoeae , AI applications for STI prevention, recombinant protein vaccines for leishmaniasis, and nanoparticle-based antimicrobial therapies. Awards : Recognized as a Hamied Foundation UK-India AMR Visiting Professor by the Academy of Medical Sciences. Research Groups : Member of the Institute for Life Sciences , contributing to interdisciplinary projects in infection research.
Benjamí Oller Salvia is an Associate Professor and ERC Grantee at the Department of Bioengineering, IQS School of Engineering, Ramon Llull University. His research focuses on developing innovative strategies for brain drug delivery and creating biotherapeutics for neurological diseases and brain tumors. He leads the ChemSynBio research group, which combines chemical and synthetic biology to create protein-based precision therapeutics. Dr. Oller Salvia's educational background includes: PhD in Organic Chemistry (University of Barcelona, 2015) MSc in Organic Chemistry (University of Barcelona, 2012) Degree in Chemistry (URL, 2010) His research interests center on the development of peptides for biomedical applications, generation of selectively modified therapeutic proteins through genetic code expansion and bioorthogonal chemistry, and design of vectorized drug delivery systems targeting the brain. He specializes in creating stimuli-responsive proteins and nanomaterials to overcome the blood-brain barrier for treating brain diseases and tumors. His work bridges chemical biology, protein engineering, and nanomedicine to develop precision therapeutics. Analysis of his recent publications shows a strong focus on brain-targeted drug delivery systems, particularly using peptidomimetics like 'BrainBike' to transport therapeutic proteins across the blood-brain barrier. His research increasingly emphasizes conditionally-activated antibodies and smart conjugates that target brain tumors while minimizing off-target effects. The work spans multiple disease areas including glioblastoma, brain metastases, and lung cancer, with a consistent theme of overcoming biological barriers through innovative molecular engineering. His notable scientific achievements include: ERC Grantee award EMBO Long-Term Fellowship (MRC Laboratory of Molecular Biology, Cambridge, 2017-2019) MRC Postdoctoral Scientist position (MRC Laboratory of Molecular Biology, Cambridge, 2016-2017) Dr. Oller Salvia actively supervises research projects and mentors students in the ChemSynBio group. He has secured multiple research grants including the EGFR-LYTAC project on lysosomal targeting chimeras for lung cancer and the SMEDs project on smart protein degraders for brain tumors. His lab collaborates extensively on interdisciplinary projects spanning chemical biology, protein engineering, and neuropharmacology. The ChemSynBio research group, which he leads, focuses on combining chemical and synthetic biology to create protein-based precision therapeutics and biomedical tools, with primary goals of treating brain tumors and understanding drug transport across the blood-brain barrier. The group operates within the broader GEMAT (Materials Engineering Group) framework at IQS.
Ilkka Nissilä, Ph.D., is a Staff Scientist at the Department of Neuroscience and Biomedical Engineering , Aalto University. With a career spanning over two decades, his work focuses on diffuse optical tomography , near-infrared spectroscopy , and neonatal brain imaging . He served as a Principal Investigator for the Academy of Finland-funded project Multimodal neuroimaging of children (2016–2018) and has collaborated internationally through visiting researcher appointments. Education : Doctoral Degree in Engineering, Helsinki University of Technology (2004) Master's Degree in Engineering, Helsinki University of Technology (1998) Research Themes : Biomedical optics and optical tomography for brain imaging Neurovascular coupling and hemodynamic responses Developmental neuroscience in infants/children Emotional and sensory processing in early life Algorithm development for image reconstruction Integration of NIRS with TMS/MEG/EEG Article Trends : Recent work combines deep learning with diffuse optical tomography for improved brain imaging Studies maternal mental health impacts on child brain development Advances frequency-domain data utilization and 3D anatomical modeling in neonatal studies Activities : Visiting Researcher (2001–2008) at multiple foreign institutions Conference Presentations Media Impact : 2023: AI-Mind General Assembly participation 2022: Co-developed a skin-stroking device for alcohol cravings 2019: Maternal anxiety effects on infant brain covered in Finnish media Collaborations : International partnerships in biomedical optics Interdisciplinary work with pediatric and psychiatric researchers
Dr. John Bell is a Professor at the University of Ottawa's Faculty of Medicine and a Cross-Appointed Member at The Ottawa Hospital Research Institute. His research focuses on oncolytic viruses, protein translation, cancer therapeutics, and biochemistry, with a mission to develop novel cancer-killing viruses that selectively target malignant cells while sparing healthy tissue. Current position: Senior Scientist (Cancer Research) at OHRI Research includes clinical translation and commercialization of therapeutic viruses His work spans the discovery, design, and manufacturing of oncolytic viruses for cancer treatment. Key research trends include combination immunotherapy , tumor microenvironment interactions , and VEGF signaling in viral targeting , with recent publications emphasizing translational applications and clinical trial frameworks. Scientific Awards: Fellow of the Royal Society of Canada (FRSC) Fellow of the Canadian Academy of Health Sciences (FCAHS) Dr. Bell leads the Bell Lab at OHRI, mentoring researchers in virology and cancer biotherapeutics. His collaborations include clinical trials and industry partnerships in oncolytic virus development.
Dr. Frederick M MacDonnell is a Professor in the Department of Chemistry and Biochemistry at The University of Texas at Arlington (UTA), College of Science. With a distinguished career spanning several decades, he has established himself as a leading researcher in inorganic chemistry, photochemistry, and catalysis. His work bridges fundamental chemical research with practical applications in energy production and cancer therapeutics. Dr. MacDonnell's research program focuses on two major areas: the development of ruthenium polypyridyl complexes for cancer treatment and heterogeneous catalysis for fuel production. His laboratory investigates the therapeutic potential and mechanisms of action of ruthenium-based compounds, particularly their ability to target microtubules and cleave DNA under hypoxic conditions. In the energy sector, his research explores natural gas-to-liquids chemistry, CO 2 reduction to methanol, and hydrogen production through catalytic processes. His work often combines photochemical and thermal approaches to achieve multi-electron reductions necessary for energy storage. Analysis of his recent publications reveals a strong trend toward applied research with industrial partnerships, particularly in catalytic processes for energy conversion. While maintaining his expertise in ruthenium chemistry for medical applications, his recent work shows increased focus on practical catalytic systems for natural gas conversion and CO 2 utilization. The research demonstrates sophisticated integration of molecular design with practical engineering considerations for scale-up. Academy of Distinguished Scholars, University of Texas at Arlington (2021) Distinguished Record of Research, UTA (2014) Outstanding Teacher Award, UTA College of Science (2012) Outstanding Research Achievement, UTA College of Science (2003) Damon Runyon Cancer Research Fellowship (1992) Dr. MacDonnell has successfully mentored numerous graduate students including Amir Jafari, Cynthia Griffith, Oluchukwu Igboenyesi, Matthew Guerrero, and Melissa Reardon. His research program has been supported by substantial funding from federal agencies including NSF, NIH, and DOE, as well as industry partners like Greenway Innovative Energy and TRT Holdings. His laboratory facilities support advanced synthesis, photochemical studies, and catalytic testing, with notable equipment including NMR spectrometers upgraded through NSF funding. Current research directions include developing more efficient catalysts for natural gas conversion and optimizing ruthenium complexes for targeted cancer therapy with reduced side effects.
Dr. Amanda N. Szabo-Reed serves as a Research Associate Professor in the Division of Weight Management at the University of Kansas Medical Center, with significant affiliations at the KU Alzheimer's Disease Center. Her academic journey includes advanced degrees from the University of Michigan and University of Illinois, Urbana-Champaign, culminating in specialized clinical research training at KU Medical Center. BS, Movement Science, University of Michigan, Ann Arbor, MI BA, Sports Management and Communications, University of Michigan, Ann Arbor, MI MS, Kinesiology, University of Illinois at Urbana-Champaign, Urbana, IL PhD, Kinesiology, University of Illinois at Urbana-Champaign, Urbana, IL MS, Clinical Research, University of Kansas Medical Center, Kansas City, KS Post Doctoral Fellowship, Weight Management, University of Kansas Medical Center, Kansas City, KS Her research program rigorously investigates how lifestyle behavioral adherence—particularly to diet and exercise—impacts mental and cognitive health across the lifespan. With over 30 peer-reviewed publications, she examines critical moderators of cognitive change including self-efficacy, self-regulation, and physiological adaptations, while developing interventions to improve brain health and quality of life. Her work spans diverse populations including older adults, individuals with Down syndrome, and those with intellectual disabilities. Dr. Szabo-Reed's publication record demonstrates consistent focus on exercise-cognition relationships, weight management interventions, and Alzheimer's disease prevention strategies. Her recent work includes leadership roles in major NIH-funded trials examining dose-response exercise effects on brain health and implementing physician-prescribed lifestyle medicine. Ruth L. Kirschstein Postdoctoral Individual National Research Service Award KL2 Mentored Clinical Research Scholar Award She actively contributes to multiple high-impact clinical trials including the COMET study (Combined Exercise Trial), LEAP! Rx, and IGNITE trial, focusing on cognitive outcomes in aging populations. Her methodological expertise spans remote intervention delivery, clinical trial management systems, and adapting research protocols during public health emergencies like the COVID-19 pandemic.
Ayşe Mizrak is a Professor at Gaziantep University's Faculty of Medicine, Department of Anesthesiology and Reanimation. She has been serving as a Professor since 2017 and currently holds the position of Department Head (2024-2027). Her academic career spans over two decades with significant contributions to the field of anesthesiology. Dr. Mizrak completed her medical education at Ege University Faculty of Medicine (1987-1993) followed by specialization in Anesthesiology and Reanimation at Erciyes University Faculty of Medicine (1999-2005). Her research primarily focuses on anesthesiology and pain management , with special emphasis on regional anesthesia techniques, perioperative care, and the effects of various anesthetic agents. Dr. Mizrak has made significant contributions to understanding optimal pain management protocols for thoracic surgeries, the application of ultrasound-guided nerve blocks, and the physiological effects of anesthetic medications on hemodynamic stability. Her work has helped advance clinical practices in airway management, particularly for challenging cases involving pediatric and geriatric patients. An analysis of her recent publications reveals a strong focus on innovative pain management techniques, particularly the use of erector spinae plane blocks, dexmedetomidine combinations, and multimodal analgesia approaches. Her research spans both clinical applications and physiological mechanisms, with studies examining hemodynamic responses during intubation, the impact of environmental factors on anesthetic requirements, and specialized techniques for various surgical procedures. Dr. Mizrak has successfully supervised 21 specialization theses and currently mentors several ongoing research projects. Her academic leadership extends to her role on the University's Quality Committee and as a jury member for specialization exams. She has taught numerous courses at all academic levels, from undergraduate to doctoral studies, with a particular focus on neuraxial blocks and central nerve blocks.
Eddy Sotelo Pérez is a Full Professor of Medicinal Chemistry at the Faculty of Pharmacy, University of Santiago de Compostela, where he leads the Sotelo Research Group (ComBioMed) within the Center for Research in Biological Chemistry and Molecular Materials (CIQUS). He holds appointments in both the Department of Organic Chemistry and the Institute of Industrial Pharmacy, directing a multidisciplinary team focused on drug discovery and development. Full Professor of Medicinal Chemistry (since April 2023) Associate Editor, Purinergic Signalling (since 2022) Principal Investigator, ComBioMed Research Group Co-founder, Celtarys Research His research spans medicinal chemistry, chemical biology, and catalysis, with particular emphasis on GPCR pharmacology for cancer immunotherapy, neurological disorders, and inflammatory diseases. The group pioneers multicomponent synthetic strategies and 3D-printed catalytic systems to accelerate drug discovery while reducing environmental impact. Analysis of recent publications reveals a strong focus on GPCR-targeted therapeutics, particularly CB2 and A2B receptors for cancer and inflammation. The group has successfully translated fluorescent probe technology to industry through Celtarys Research, eliminating radioactive compounds in drug screening. Recent work integrates 3D printing with heterogeneous catalysis to develop sustainable pharmaceutical manufacturing processes. Fernando Calvet Prats award from Royal Galician Academy of Sciences (2022) Celtarys Research finalist in Royal Society of Chemistry Emerging Technologies Competition Multiple patents on catalytic systems and fluorescent probes Sotelo actively mentors doctoral students across multiple projects including CAPN12-IO (calpain-12 inhibitors for cancer immunotherapy) and PREDICTEAM (immune checkpoint analysis). His research has secured significant funding from MCIN, AEI, EU NextGeneration, and Xunta de Galicia. The Sotelo Lab maintains strong industry collaborations with pharmaceutical companies to translate basic research into therapeutic applications. The group operates advanced facilities for combinatorial chemistry, molecular imaging, and 3D-printed catalysis, with particular expertise in developing fluorescent alternatives to radioactive compounds for high-throughput screening. Current work focuses on multi-target immunotherapies and novel catalytic systems for sustainable pharmaceutical manufacturing.
Craig A. Bunnell is an Associate Professor of Medicine at Harvard Medical School and the Morse Family Chief Medical Officer of the Dana-Farber Cancer Institute , a Harvard-affiliated NCI-designated Comprehensive Cancer Center. He is a breast medical oncologist with expertise in clinical trials , cancer care delivery , and healthcare systems innovation . MD and PhD in Medicine from Harvard Medical School MBA from Massachusetts Institute of Technology Completed residency and fellowship at Brigham and Women's Hospital His research focuses on novel agents for breast cancer , chemotherapy safety , and operational efficiency in oncology . He pioneered trastuzumab-vinorelbine combination therapy for HER2-positive breast cancer and conducted foundational work on weekly taxane regimens . Current studies include DPYD testing for fluoropyrimidine safety and multidisciplinary care pathways . Scientific contributions span 120+ publications in areas like symptom control , genomic testing , and healthcare technology implementation . Notable awards include the Bass Scholar distinction (2000) and Boston Business Journal's Champion in Healthcare (2010) for industry innovation. Leadership roles include positions at the National Comprehensive Cancer Centers , American Society of Clinical Oncology , and Association of American Cancer Institutes . He has developed real-time locating systems (RTLS) for clinic optimization and studied patient compliance with oral chemotherapies .
Steven L. Stice is the D.W. Brooks Distinguished Professor and Georgia Research Alliance Eminent Scholar in Animal Reproductive Physiology at the University of Georgia . He serves as Director of the Regenerative Bioscience Center and co-leads the NSF-funded $50M Engineering Research Center for Cell Manufacturing Technologies (CMaT). His work bridges academia and industry as co-founder of five biotech companies, including Aruna Biomedical, which has achieved FDA clearance for the first U.S. clinical trial using exosomes to treat acute ischemic stroke. BS, University of Illinois MS, Iowa State University PhD, University of Massachusetts Dr. Stice's research focuses on regenerative medicine , exosome technology , and neurological disease treatment . His lab develops neural stem cell-derived extracellular vesicles for brain repair after stroke or traumatic injury, with emphasis on cell-based assays for drug discovery. His recent publications highlight advancements in exosome therapeutic delivery, stroke recovery models, and metabolomic approaches to cell therapy potency. Key collaborations include Regenerative Engineering and Medicine (REM) with Emory and Georgia Tech, and leadership roles at the FDA Scientific Advisory Board. 225+ scholarly articles 14,000+ citations 67 international patents 16 U.S. patents National Academy of Inventors Fellow Regents’ Entrepreneur distinction National Football Foundation Distinguished American Award Southeastern Conference Faculty Achievement Award Dr. Stice mentors through the Regenerative Bioscience Center , which involves 35+ researchers across six colleges. His work has attracted major funding from NIH, NSF, DARPA, and the Bill & Melinda Gates Foundation.
Ghaith Abu-Zeinah, M.D. is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at NewYork-Presbyterian Hospital. He specializes in Myeloproliferative Neoplasms (MPNs) through the Richard T. Silver MPN Center, maintaining a dual clinical-research practice focused on MPN therapeutics and malignant stem cell targeting. Education: M.D. with academic distinction from Weill Cornell Medical College, Cornell University (2013) Residency in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medicine (2016) Fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medicine (2019) His research bridges translational science and clinical care, with emphasis on developing curative MPN treatments through malignant stem cell targeting. Current work leverages machine learning for risk prediction models and automated extraction of hematopathology data. Clinical expertise spans Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, and Chronic Myeloid Leukemia. Recent publications demonstrate leadership in MPN clinical trials (EXCEED-ET, ECLIPSE-PV, PARADIGM-PV), pharmacovigilance studies, and pandemic-era hematology research through the EPICOVIDEHA registry. His work frequently addresses treatment safety, risk stratification, and novel therapeutic approaches in MPNs. No specific scientific awards are listed in available materials, though his bio notes he has received several awards for his work and presented at major conferences including the International Congress on MPNs and American Society of Hematology. Dr. Abu-Zeinah maintains active clinical practice at the Richard T. Silver MPN Center (520 East 70th Street, New York) and leads research funded by the American Society of Hematology (2024-2027) on predicting disease progression in Polycythemia Vera using machine learning. His external collaborations include consulting roles with Dr AZ Consulting LLC and Slingshot Insights Inc.
Dr. Michael Pape serves as Professor of Practice in the Department of Management at the University of Central Florida's College of Business Administration, where he has taught entrepreneurship since 2015. As Dr. Phillips Entrepreneur in Residence, he directs the Upstarts Venture Incubation Program at UCF's Center for Entrepreneurial Leadership, guiding students through his proprietary Startup Staircase ® framework for venture development. His educational credentials include: B.S. in Microbiology from the University of Michigan Ph.D. in Biochemistry from Purdue University MBA from the University of Chicago Booth School of Business Dr. Pape's research spans biotechnology entrepreneurship and venture incubation methodologies , with expertise in problem-solving at the science-technology-business interface . He developed the Startup Staircase ® framework for competency-based entrepreneurial education, used by startups and corporations for innovation. His industry background in lipid metabolism research (1980s-2000s) evolved into contemporary focus on entrepreneurial methodology, reflecting his dual career in biotech ventures and academia. His scholarly output demonstrates a clear trajectory from biochemical research on lipid disorders and cardiovascular drug development to entrepreneurship education, with recent publications emphasizing venture incubation in emerging economies and student-led consulting models. Recognition includes: Distinguished Alumni Award from University of Chicago Booth School of Business Distinguished Alumni Award from Purdue University College of Agriculture As an advisor, Dr. Pape mentors UCF entrepreneurial students through Upstarts while serving on Base4 Biotechnology's board. His industry impact includes co-founding Esperion Therapeutics (acquired by Pfizer for $1.3B), Akebia Therapeutics (IPO 2014), and Orchard Venture Partners. He previously led the Michigan Academy for Developing Entrepreneurs (2017-2024), supporting entrepreneurs in emerging economies through consulting and training programs. Dr. Pape directs UCF's Upstarts Venture Incubation Program and maintains active industry engagement through Base4 Biotechnology's scientific advisory team, facilitating university-industry partnerships for translational research and startup formation.
Meneghini Vasco is a Fixed-term Researcher (RTD-A) in Human Histology at Vita-Salute San Raffaele University's School of Medicine and Surgery in Milan, Italy. His academic career spans prestigious institutions including San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Imagine Institute of Genetic Diseases in Paris, and University of Piemonte Orientale. Ph.D. in Food and Pharmaceutical Biotechnologies, University of Piemonte Orientale (2010) Master Degree in Industrial Biotechnology, University of Milan-Bicocca (2006) Bachelor in Molecular Biotechnology, University of Milan-Bicocca (2003) Dr. Meneghini's research focuses on gene therapy for lysosomal storage diseases , CRISPR/Cas9 genome editing applications , and neural stem cell engineering . His work integrates advanced techniques in viral vector development, iPSC modeling, and hematopoietic stem cell manipulation to address neurological and hematological disorders. Current projects emphasize AAV vector optimization, immune response characterization, and developing allele-specific editing strategies for neurodegenerative conditions. His publication record reveals a strong emphasis on translational neuroscience and regenerative medicine , with recent work (2022-2025) concentrating on AAV vector immunogenicity, neural stem cell safety profiles, and combinatorial genome editing approaches for sickle cell disease. Key trends include developing safer CNS delivery systems, optimizing iPSC-derived neural models, and advancing precision editing techniques for monogenic disorders. NextGenerationEU-PNRR grant, Italian Ministry of University and Research (2022) BGTC AAV Biology research program (Co-PI), Foundation for the National Institutes of Health (2022) Marie Skłodowska Curie Actions Individual Fellowship (2020) Ricerca Finalizzata - Giovani Ricercatori grant, Italian Ministry of Health (2019) Sanofi iAwards Europe (2019) As Project Leader at SR-Tiget's Gene and Neural Stem Cell Therapy Unit, Meneghini directs research on lysosomal storage disease therapies while serving on editorial boards for Frontiers journals. His collaborative network spans European and American gene therapy consortia, with significant contributions to international sickle cell disease research initiatives and European Leukodystrophies Association family-researcher engagement programs. Meneghini maintains active laboratory operations at San Raffaele-Telethon Institute, leading a multidisciplinary team focused on vector development, neural stem cell characterization, and preclinical validation of gene editing approaches. His group collaborates extensively with clinical teams at San Raffaele Hospital and international consortia including the European Society of Gene and Cell Therapy.
Dr. R.F. Kornelisse is a Researcher at Erasmus MC specializing in Neonatal and Pediatric Intensive Care. With an extensive publication record of 79 research outputs, Dr. Kornelisse's work primarily focuses on neonatal critical care, sepsis management, and pharmacokinetics in neonates and infants. Dr. Kornelisse's research interests span across several critical areas in neonatology including: Neonatal sepsis diagnosis and management Pharmacokinetics and antibiotic dosing in neonates Neonatal intensive care unit (NICU) infections Antenatal corticosteroid administration in high-risk pregnancies Gestational age-related outcomes in neonates Blood culture diagnostics for early-onset sepsis Analysis of Dr. Kornelisse's recent publications (2024-2025) reveals a strong focus on optimizing treatment protocols for neonates, particularly in the areas of sepsis management and antibiotic therapy. The research demonstrates a multidisciplinary approach combining clinical neonatology, infectious disease management, and pharmacokinetic modeling to improve outcomes for vulnerable neonatal populations. Much of the work involves large multicenter cohort studies that provide robust evidence for clinical practice, including research on clavulanic acid pharmacokinetics, antenatal corticosteroid timing, and PCR testing for sepsis diagnosis. Dr. Kornelisse has collaborated extensively with researchers across Dutch medical institutions on neonatal care topics, contributing to important clinical guidelines in the field. The research has gained attention in academic circles with citations and mentions in news outlets, blogs, and social media platforms.
